Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Pricing might be...

    Pricing might be tested with costly eye therapy: Novartis

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2018-11-26T09:38:14+05:30  |  Updated On 26 Nov 2018 9:38 AM IST
    Pricing might be tested with costly eye therapy: Novartis

    ZURICH: Novartis price-setting muscle is about to be tested after it won European Union approval for a blindness-fighting gene therapy whose $850,000 list cost in the United States has been labelled too expensive by some groups.


    Luxturna, sold by Spark Therapeutics in the United States and by Novartis elsewhere after the Swiss drugmaker bought the rights, is a one-time treatment for a rare genetic disease that causes blindness in about 1 in 200,000 people.


    “EU approval of the one-time gene therapy Luxturna marks a milestone in reimagining medicine and can bring real value to patients, their families and society as a whole,” said Paul Hudson, who heads up Novartis’s drugs division.





    The therapy’s list price, however, has raised eyebrows and could face hurdles in Europe where authorities are taking a tough look at expensive medicines.



    Earlier this year, a non-profit U.S. cost-effectiveness watchdog, the Boston-based Institute for Clinical and Economic Review (ICER), labelled Luxturna too expensive and suggested steep discounts to make it worth their while.


    With European Union approval in hand, Novartis now must convince cost-conscious government price regulators across the bloc and in non-members such as Switzerland to pay up to start selling the drug.






    Among others, Britain’s National Institute for Health and Care Excellence (NICE) has been pushing back at companies demanding high prices, including a Vertex Pharmaceuticals cystic fibrosis drug and Biogen’s (
    BIIB.O
    ) $750,000 Spinraza treatment for spinal muscular atrophy (SMA).




    “If you consider that this is a one-time treatment of a condition that otherwise leads to blindness, then it seems like the sum being demanded is acceptable,” Zuercher Kantonalbank analyst Michael Nawrath said.



    PRICE CLAMPDOWN


    “Even so, the price negotiations in Europe cannot be underestimated, because drug companies are focusing more and more on rare diseases, while the authorities are seeking to reduce incentives by clamping down on prices,” Nawrath said.












    Novartis Chief Executive Officer Vas Narasimhan is banking on rare diseases to help transform the Basel-based company from a broad healthcare conglomerate into a specialized drug company.





    In addition to his deal with Spark over Luxturna, Narasimhan has a stable of prospective gene therapies, including a one-time treatment for SMA due for approval in the first half of 2019.


    That drug, AVXS-101, will likely be even more expensive than Luxturna, as Novartis has already pegged its value at between $4-$5 million for healthcare systems. Payers have already started putting up resistance.


    Also Read: Novartis Luxturna Gene Therapy for restoring Eyesight in Rare retinal diseases gets European Approval
    approvalblindnessEUeye therapygene therapyLuxturnaNICENovartispriceSMAspark therapeutictestUS
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok